NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP has commenced an investigation of ACADIA Pharmaceuticals Inc. (NASDAQGS:ACAD) in connection with possible violations of federal securities laws.
To get more information, click here: http://zlk.9nl.com/acadia-pharmaceuticals-acad. There is no cost or obligation to you.
On March 11, 2015, the Company announced it would delay submitting a New Drug Application for its drug Nuplazid. The Company also noted that Chief Executive Officer Uli Hacksell is retiring. Shares of ACADIA were down more than 20% on intraday trading the following day.
If you own common stock in ACADIA and wish to obtain additional information about the investigation, please contact Eduard Korsinsky, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/acadia-pharmaceuticals-acad.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.